|
Vaccine study of MVA-MUC1-IL2 in patients with Prostate Cancer Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Vaccine study of MVA-MUC1-IL2 in patients with Prostate Cancer conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Vaccine study of MVA-MUC1-IL2 in patients with Prostate Cancer Clinical research trials and Vaccine study of MVA-MUC1-IL2 in patients with Prostate Cancer health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Vaccine study of MVA-MUC1-IL2 in patients with Prostate Cancer. Vaccine study of MVA-MUC1-IL2 in patients with Prostate Cancer Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Vaccine study of MVA-MUC1-IL2 in patients with Prostate Cancer clinical trial. Participants oftentimes recieve the most expert healthcare available for their Vaccine study of MVA-MUC1-IL2 in patients with Prostate Cancer condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "V" Clinical Trials Conditions > Vaccine study of MVA-MUC1-IL2 in patients with Prostate Cancer  Vaccine study of MVA-MUC1-IL2 in patients with Prostate Cancer
Vaccine study of MVA-MUC1-IL2 in patients with Prostate Cancer
For Condition: Prostatic Neoplasms
Status: Recruiting
Sponsor(s): Transgene , University of California, Los Angeles,Cleveland Clinic Foundation Hospital,Arizona Medical Center,University of Chicago
Synopsis: This study involves the use of an experimental product, TG4010. The purpose of the study is to determine if TG4010 can stimulate the body's immune system to help it fight the cancer.
Details: The experimental product, TG4010, is a modified vaccinia virus (already used in humans) into which two (2) genes have been placed. One gene is for a protein (MUC1) found in cancer cells. The second gene is for human interleukin 2 (IL2) which the body's immune system makes to help it fight cancer. The TG4010 is given as an injection under the skin (subcutaneous) once a week for six weeks followed by a schedule of every three weeks or every three weeks for the first twelve (12) weeks. If the therapy is working, it can be continued for up to 9 months until no further improvement or until the patient gets worse for as long as it is tolerated.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Male
Protocol Entry Criteria: Inclusion Criteria: - Rising PSA after surgery or radiation for prostate cancer Exclusion Criteria: - Metastasis or local disease - Prior hormone treatment
Total Enrollment: 50
Location and Contact Information:
Cleveland Clinic Foundation *Recruiting*
Cleveland, Ohio, 44195
United States
Recruiting Jason Rothaermel 216-445-3741
Arizona Cancer Center *Recruiting*
Tucson, Arizona, 85724
United States
Recruiting Carol Sesma 520-626-9008
University of Chicago *Recruiting*
Chicago, Illinois, 60637
United States
Recruiting Chinyere Okoroh 773-702-6792
UCLA *Recruiting*
Los Angeles, California, 90095
United States
Recruiting Annette Tan 310-267-2336
Additional Information:
Study ID Numbers: TG4010.03;
Study Start Date: May 2002
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00040170
Other Prostatic Neoplasms Studies:
1. Massage Therapy for Cancer-Related Fatigue
2. A Phase I Study of Recombinant Vaccinia Virus that Expresses Prostate Specific Antigen in Adult Patients with Adenocarcinoma of the Prostate
3. A Phase 1/2 Dose Escalation Trial of Multiple Doses of MLN2704 in Subjects with Metastatic Androgen-Independent Prostate Cancer
4. A Phase 1, evaluation of Transgenic Lymphocyte Immunization vaccine in subjects with prostate adenocarcinoma.
5. Vaccine study of MVA-MUC1-IL2 in patients with Prostate Cancer
Related Studies:
Other Prostatic Neoplasms Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Vaccine study of MVA-MUC1-IL2 in patients with Prostate Cancer
|
|
|
|
|
|
|
|
